Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BDTX Black Diamond Therapeutics	$2.50 +5.5%	$1.69	$1.20 ▼ $6.75	$142.16M	2.63	1.51 million shs	1.90 million shs
IGXT IntelGenx Technologies	$0.17	$0.17	$0.09 ▼ $0.22	$29.17M	2.47	N/A	N/A
KYTX Kyverna Therapeutics	$2.79 +5.3%	$2.14	$1.78 ▼ $16.64	$120.58M	2.52	419,847 shs	356,382 shs
NMRA Neumora Therapeutics	$0.74 -0.6%	$0.74	$0.61 ▼ $17.19	$120.20M	2.96	1.51 million shs	607,193 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BDTX Black Diamond Therapeutics	+6.28%	+17.91%	+33.15%	+30.94%	-50.42%
IGXT IntelGenx Technologies	0.00%	0.00%	0.00%	0.00%	0.00%
KYTX Kyverna Therapeutics	+5.16%	+16.74%	+16.23%	+0.76%	-78.85%
NMRA Neumora Therapeutics	+5.44%	+10.03%	-3.65%	-46.96%	-92.45%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BDTX Black Diamond Therapeutics	3.1724 of 5 stars	3.5	4.0	0.0	0.0	2.7	2.5	0.6
IGXT IntelGenx Technologies	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
KYTX Kyverna Therapeutics	1.791 of 5 stars	3.6	1.0	0.0	0.0	2.6	1.7	0.0
NMRA Neumora Therapeutics	3.0977 of 5 stars	4.1	0.0	0.0	0.0	3.4	2.5	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BDTX Black Diamond Therapeutics	3.00	Buy	$14.60	484.00% Upside
IGXT IntelGenx Technologies	0.00	N/A	N/A	N/A
KYTX Kyverna Therapeutics	3.14	Buy	$18.50	563.08% Upside
NMRA Neumora Therapeutics	2.22	Hold	$9.29	1,149.59% Upside

Current Analyst Ratings Breakdown

Latest IGXT, BDTX, NMRA, and KYTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/27/2025	KYTX Kyverna Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$4.00 ➝ $5.00
5/13/2025	NMRA Neumora Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
4/10/2025	NMRA Neumora Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
4/3/2025	KYTX Kyverna Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$6.00 ➝ $4.00
4/2/2025	NMRA Neumora Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Underperform	$7.00 ➝ $1.00
4/1/2025	KYTX Kyverna Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$40.00 ➝ $20.00
3/19/2025	BDTX Black Diamond Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$11.00
3/18/2025	BDTX Black Diamond Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$11.00 ➝ $12.00
3/10/2025	NMRA Neumora Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
3/7/2025	BDTX Black Diamond Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$16.00 ➝ $15.00
3/7/2025	BDTX Black Diamond Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$16.00 ➝ $11.00

(Data available from 6/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BDTX Black Diamond Therapeutics	$70M	2.03	N/A	N/A	$2.26 per share	1.11
IGXT IntelGenx Technologies	$1.04M	28.05	N/A	N/A	($0.07) per share	-2.39
KYTX Kyverna Therapeutics	$7.03M	17.15	N/A	N/A	N/A	∞
NMRA Neumora Therapeutics	N/A	N/A	N/A	N/A	$3.07 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BDTX Black Diamond Therapeutics	-$82.44M	$0.06	N/A	N/A	N/A	N/A	-68.08%	-49.65%	8/5/2025 (Estimated)
IGXT IntelGenx Technologies	-$9.93M	-$0.06	N/A	∞	N/A	N/A	N/A	N/A	N/A
KYTX Kyverna Therapeutics	-$60.37M	-$3.38	N/A	N/A	N/A	N/A	-51.12%	-37.91%	8/11/2025 (Estimated)
NMRA Neumora Therapeutics	-$235.93M	-$1.61	N/A	N/A	N/A	N/A	-73.63%	-68.97%	8/5/2025 (Estimated)

Latest IGXT, BDTX, NMRA, and KYTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	KYTX Kyverna Therapeutics	-$1.21	-$1.03	+$0.18	-$1.03	N/A	N/A
5/12/2025	Q1 2025	NMRA Neumora Therapeutics	-$0.40	-$0.42	-$0.02	-$0.42	N/A	N/A
3/27/2025	Q4 2024	KYTX Kyverna Therapeutics	-$0.87	-$0.88	-$0.01	-$0.88	N/A	N/A
3/6/2025	Q4 2024	BDTX Black Diamond Therapeutics	-$0.31	-$0.28	+$0.03	-$0.28	N/A	N/A
3/6/2025	Q4 2024	NMRA Neumora Therapeutics	-$0.46	-$0.37	+$0.09	-$0.37	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BDTX Black Diamond Therapeutics	N/A	N/A	N/A	N/A	N/A
IGXT IntelGenx Technologies	N/A	N/A	N/A	N/A	N/A
KYTX Kyverna Therapeutics	N/A	N/A	N/A	N/A	N/A
NMRA Neumora Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BDTX Black Diamond Therapeutics	N/A	5.55	5.55
IGXT IntelGenx Technologies	N/A	N/A	N/A
KYTX Kyverna Therapeutics	N/A	10.50	10.50
NMRA Neumora Therapeutics	N/A	10.98	10.98

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BDTX Black Diamond Therapeutics	95.47%
IGXT IntelGenx Technologies	N/A
KYTX Kyverna Therapeutics	18.08%
NMRA Neumora Therapeutics	47.65%

Insider Ownership

Company	Insider Ownership
BDTX Black Diamond Therapeutics	5.97%
IGXT IntelGenx Technologies	42.05%
KYTX Kyverna Therapeutics	22.00%
NMRA Neumora Therapeutics	26.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BDTX Black Diamond Therapeutics	90	56.86 million	51.57 million	Optionable
IGXT IntelGenx Technologies	38	174.66 million	101.21 million	Not Optionable
KYTX Kyverna Therapeutics	96	43.22 million	N/A	Optionable
NMRA Neumora Therapeutics	108	161.75 million	118.91 million	Optionable

IGXT, BDTX, NMRA, and KYTX Headlines

Recent News About These Companies

Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Average Recommendation of "Hold" by Analysts

June 1 at 3:48 AM | marketbeat.com

Kuehn Law Encourages Investors of Neumora Therapeutics, Inc. to Contact Law Firm

May 27, 2025 | globenewswire.com

Neumora Therapeutics’s SWOT analysis: navigating challenges in neuropsychiatric drug development

May 24, 2025 | uk.investing.com

Softbank Group CORP. Has $69.34 Million Position in Neumora Therapeutics, Inc. (NASDAQ:NMRA)

May 18, 2025 | marketbeat.com

HC Wainwright Has Pessimistic Outlook of NMRA Q2 Earnings

May 17, 2025 | marketbeat.com

Q2 EPS Forecast for Neumora Therapeutics Raised by Analyst

May 17, 2025 | marketbeat.com

Neumora Therapeutics, Inc. (NASDAQ:NMRA) Shares Sold by Price T Rowe Associates Inc. MD

May 17, 2025 | marketbeat.com

Needham & Company LLC Reiterates "Buy" Rating for Neumora Therapeutics (NASDAQ:NMRA)

May 15, 2025 | marketbeat.com

Neumora Therapeutics, Inc. (NASDAQ:NMRA) Stock Holdings Lessened by Orbimed Advisors LLC

May 15, 2025 | marketbeat.com

Neumora Therapeutics (NASDAQ:NMRA) Posts Earnings Results, Misses Expectations By $0.02 EPS

May 14, 2025 | marketbeat.com

Kuehn Law Encourages Investors of Neumora Therapeutics, Inc. to Contact Law Firm

May 14, 2025 | prnewswire.com

Neumora Therapeutics, Inc.: Neumora Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 13, 2025 | finanznachrichten.de

Neumora Therapeutics Inc (NMRA) Q1 2025 Earnings Call Highlights: Advancing Brain Disease ...

May 13, 2025 | finance.yahoo.com

Neumora Therapeutics, Inc. (NMRA) Q1 2025 Earnings Call Transcript

May 12, 2025 | seekingalpha.com

Neumora Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 12, 2025 | globenewswire.com

Will Neumora Therapeutics (NASDAQ:NMRA) Spend Its Cash Wisely?

May 11, 2025 | finance.yahoo.com

Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Average Rating of "Hold" by Analysts

May 9, 2025 | marketbeat.com

Schonfeld Strategic Advisors LLC Increases Stake in Neumora Therapeutics, Inc. (NASDAQ:NMRA)

May 5, 2025 | marketbeat.com

Neumora Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025

April 28, 2025 | globenewswire.com

Why Neumora Therapeutics, Inc.’s (NMRA) Stock Is Up 10.34%

April 23, 2025 | aaii.com

Kuehn Law Encourages Investors of Neumora Therapeutics, Inc. to Contact Law Firm

April 16, 2025 | investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IGXT, BDTX, NMRA, and KYTX Company Descriptions

Black Diamond Therapeutics NASDAQ:BDTX

$2.50 +0.13 (+5.49%)

Closing price 04:00 PM Eastern

Extended Trading

$2.50 +0.00 (+0.20%)

As of 05:33 PM Eastern

Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

IntelGenx Technologies OTCMKTS:IGXT

$0.17 0.00 (0.00%)

As of 05/27/2025

IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine; INT0046/2018 and INT0055/2021 are for adult use; INT0007/2006, an oral film product for treatment of erectile dysfunction; INT0043/2015, an oral film containing montelukast for treatment of Alzheimer and Parkinsons; INT0027/2011 to treat opioid addition; INT0010/2006 for treatment of neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, an oral film product for schizophrenia or bipolar 1 disorder; and INT0048/2020 for animal health. It is also develops INT0039/2013 for pain; and INT0053/2020 for the treatment of resistant depression. The company has licensing, development, and supply agreement with Tilray, Inc.; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.

Kyverna Therapeutics NASDAQ:KYTX

$2.79 +0.14 (+5.28%)

Closing price 04:00 PM Eastern

Extended Trading

$2.90 +0.11 (+3.76%)

As of 05:25 PM Eastern

Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.

Neumora Therapeutics NASDAQ:NMRA

$0.74 0.00 (-0.64%)

Closing price 04:00 PM Eastern

Extended Trading

$0.74 +0.00 (+0.12%)

As of 04:55 PM Eastern

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time